1. The targeting on Legumain lipid containing at Legumain targeting lipid component covalently bonded to the binding gruppoy.2 Legumain. Legumain for targeting lipid of claim 1, wherein the binding group comprises Legumain Legumain inhibitor type aza-Asn peptida.3. Legumain for targeting lipid of claim 2, wherein the inhibitor of type Legumain aza-Asn is an inhibitor of type Legumain aza-Asn Mihaelya.4 acceptor. Legumain for targeting lipid of claim 1, wherein the lipid component comprises 1,2-diatsilglitserofosfoalkanolamin and Legumain binding group is bound to the amino group of 1,2-diatsilglitserofosfoalkanolamina.5. Legumain for targeting lipid of claim 4, wherein the 1,2-diatsilglitserofosfoalkanolamin comprises 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) .6. Legumain for targeting lipid of claim 1, wherein Legumain linking group comprises a group represented by formula (I) :, which is an inhibitor of type Legumain aza-Asn Mihaelya.7 acceptor. Legumain for targeting lipid of claim 1 wherein the targeting lipid on Legumain comprises a compound of formula (II): 8. A composition for targeting Legumain nanoparticles containing lipid nanoparticles, wherein the nanoparticles comprise as a targeting component in their Legumain lipid according to any one pp.1-7.9. A composition for targeting Legumain nanoparticle of claim 8, wherein at Legumain targeting lipid is mixed with one or more other micelle or vesicle forming lipid materials in nanochastitsah.10. Legumain is aimed at nanoparticulate composition according to claim 8, wherein the nanoparticles comprise (a) a targeting lipid on Legumain, (b) zwitterionic lipid component (C) an amino-substituted lipid components of1. Нацеливающий на легумаин липид, содержащий нацеливающий на легумаин липидный компонент, ковалентно связанный со связывающей легумаин группой.2. Нацеливающий на легумаин липид по п.1, где связывающая легумаин группа содержит ингибитор легумаина типа аза-Asn пептида.3. Нацеливающий на легумаин
